Investor
Relations

We are committed to developing transformational biologic medicines to serve patients with debilitating diseases

Committee Composition

	Audit Committee	Compensation Committee	Nominating and Corporate Governance Committee
Graham K. Cooper	Audit Committee	Compensation Committee
Helen S. Kim	Audit Committee
David Lamond		Compensation Committee	Nominating and Corporate Governance Committee
Holly Schachner, M.D.		Compensation Committee	Nominating and Corporate Governance Committee
Aaron VanDevender	Audit Committee		Nominating and Corporate Governance Committee